NURIX THERAPEUTICS Business Summary

Nurix Therapeutics Inc (NRIX) is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule therapies that modulate cellular protein levels through the recruitment of E3 ligases. The company generates revenue primarily through high-value strategic collaborations and licensing agreements with global pharmaceutical leaders, including Sanofi, Gilead Sciences, and Pfizer, which provide upfront payments, research funding, and milestone-based incentives. As of early 2026, Nurix operates as a single business segment focused on its proprietary DELigase platform, which integrates DNA-encoded libraries with artificial intelligence (DEL-AI) to target previously "undruggable" proteins. Its primary clinical pipeline is led by bexobrutideg (NX-5948), currently in registrational trials for B-cell malignancies. Nurix competes directly with other targeted protein degradation (TPD) specialists such as Kymera Therapeutics, Arvinas, and BeiGene. Within this landscape, Nurix distinguishes itself through its specific expertise in E3 ligase regulation and its leading position in the post-BTK inhibitor market for chronic lymphocytic leukemia. Founded in 2009 by renowned scientists Michael Rape, Ph.D. (UC Berkeley), Arthur Weiss, M.D., Ph.D. (UCSF), and John Kuriyan, Ph.D. (Vanderbilt), the company is led by President and CEO Arthur T. Sands, M.D., Ph.D., the former co-founder and CEO of Lexicon Pharmaceuticals. The executive team includes Chief Technical Officer Pasit Phiasivongsa, Ph.D., who previously held leadership roles at Kymera and Kronos Bio, and Chief Scientific Officer Gwenn M. Hansen, Ph.D., a veteran of Lexicon and Baylor College of Medicine. Financial operations are overseen by CFO Hans van Houte, formerly of Vertex Pharmaceuticals, while clinical strategy is directed by CMO Paula G. O’Connor, M.D. The company is backed by prominent institutional investors including Point72 Asset Management, T. Rowe Price, and Soleus Capital. Its Board of Directors, chaired by Julia P. Gregory, features industry stalwarts such as Roger Dansey, M.D. (formerly of Seagen and Merck) and Anil Kapur, reflecting a deep pedigree in oncology commercialization and drug development.